<p>Bright Minds Biosciences Inc.（纳斯达克代码：DRUG - 获取免费报告）的股票在目前覆盖该公司的八家券商中获得了平均 “买入” 评级，MarketBeat.com 报道。一位研究分析师给予该股票持有评级，六位分析师给予买入评级，还有一位分析师对该公司给予强烈买入评级。在过去一年中，覆盖该股票的券商的平均一年目标价为 82.50 美元。</p>
<ul>
<li>生物科技处于边缘：两只潜力巨大的股票</li>
</ul>
<p>DRUG 最近成为几份研究报告的主题。Chardan Capital 在 11 月 19 日的研究报告中将 Bright Minds Biosciences 的股票评级上调至 “强烈买入”。Zacks Research 在 12 月 2 日的报告中将 Bright Minds Biosciences 的股票评级从 “强烈买入” 下调至 “持有”。Cantor Fitzgerald 在 12 月 1 日的报告中重申了对 Bright Minds Biosciences 股票的 “增持” 评级。Wall Street Zen 在 10 月 3 日的研究报告中将 Bright Minds Biosciences 的股票评级从 “持有” 下调至 “卖出”。最后，BTIG Research 在 9 月 8 日的研究报告中开始覆盖 Bright Minds Biosciences，给予 “买入” 评级和 72.00 美元的价格目标。</p>
<p><strong>获取我们关于 DRUG 的最新股票报告</strong></p>
<h2>对 Bright Minds Biosciences 的对冲基金看法</h2>
<ul>
<li>Bright Minds Biosciences 股票暴涨近 1500%</li>
</ul>
<p>机构投资者最近调整了对该公司的持股。Braidwell LP 在第三季度以约 18422000 美元的估值收购了 Bright Minds Biosciences 的新头寸。Vivo Capital LLC 在第三季度将其在 Bright Minds Biosciences 的股份增加了 99.4%。Vivo Capital LLC 现在拥有 501,617 股该公司的股票，估值为 30428000 美元，此前在此期间又收购了 250,045 股。Balyasny Asset Management L.P. 在第三季度以约 11339000 美元的估值收购了 Bright Minds Biosciences 的新头寸。Millennium Management LLC 在第一季度将其在 Bright Minds Biosciences 的股份增加了 376.9%。Millennium Management LLC 现在拥有 192,557 股该公司的股票，价值 6946000 美元，此前在此期间又收购了 152,178 股。最后，Adage Capital Partners GP L.L.C. 在第一季度将其在 Bright Minds Biosciences 的股份增加了 50.9%。Adage Capital Partners GP L.L.C. 现在拥有 200,000 股该公司的股票，价值 7214000 美元，此前在上个季度又购买了 67,500 股。机构投资者持有该公司 40.52% 的股票。</p>
<h2>Bright Minds Biosciences 价格表现</h2>
<p>DRUG 周四开盘价为 88.83 美元。该公司的市值为 6.9195 亿美元，市盈率为-95.51，贝塔值为-6.22。Bright Minds Biosciences 的 52 周低点为 23.17 美元，52 周高点为 97.75 美元。该公司的 50 日移动平均线为 65.84 美元，200 日移动平均线为 47.14 美元。</p>
<h2>关于 Bright Minds Biosciences</h2>
<p>（获取免费报告）</p>
<p>Bright Minds Biosciences Inc. 是一家生物技术公司，开发治疗药物以改善美国患者的生活，特别是那些患有严重和改变生活的疾病。其选择性 5-HT 受体激动剂的产品组合包括用于治疗癫痫、疼痛和神经精神疾病的 5-HT2C、5-HT2A 和 5-HT2C/A，以及完成针对未披露癫痫病的 1 期试验的 BMB-101。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票，胜过 Bright Minds Biosciences</li>
<li>现在购买的三只最佳蓝筹股</li>
<li>在上涨 35% 后，分析师关注铜业巨头 Freeport 的更多上涨空间</li>
<li>券商排名在股票选择中的重要性</li>
<li>为什么 SpaceX 的 IPO 可能成为 GOOGL 股票的重大催化剂</li>
<li>股票情绪分析：如何运作</li>
<li>Upwork 能否维持其复苏？看涨和看跌的理由</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFJVRw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFJVRw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Bright Minds Biosciences 吗？</h2>
<p>在你考虑 Bright Minds Biosciences 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Bright Minds Biosciences 并不在名单上。</p>
<p>虽然 Bright Minds Biosciences 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

DRUG

<p>Bright Minds Biosciences Inc.（纳斯达克代码：DRUG）获得了八家券商的一致 “买入” 评级，平均一年目标价为 82.50 美元。机构投资者显著增加了持股，推动股价上涨近 1500%。该公司开发针对严重疾病的治疗药物，市值为 6.9195 亿美元。尽管获得了 “买入” 评级，但顶级分析师建议其他股票可能提供更好的投资机会</p>

<p>Shares of Bright Minds Biosciences Inc. (NASDAQ:DRUG - Get Free Report) have received an average rating of &#34;Buy&#34; from the eight brokerages that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation, six have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokers that have covered the stock in the last year is $82.50.</p>
<div class="lb-trans"><p>Bright Minds Biosciences Inc.（纳斯达克代码：DRUG - 获取免费报告）的股票在目前覆盖该公司的八家券商中获得了平均 “买入” 评级，MarketBeat.com 报道。一位研究分析师给予该股票持有评级，六位分析师给予买入评级，还有一位分析师对该公司给予强烈买入评级。在过去一年中，覆盖该股票的券商的平均一年目标价为 82.50 美元。</p>
</div><ul>
<li>Biotechs on the Brink: 2 Stocks With Huge Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>生物科技处于边缘：两只潜力巨大的股票</li>
</ul>
</div><p>DRUG has been the topic of several recent research reports. Chardan Capital raised shares of Bright Minds Biosciences to a &#34;strong-buy&#34; rating in a research report on Wednesday, November 19th. Zacks Research downgraded shares of Bright Minds Biosciences from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Tuesday, December 2nd. Cantor Fitzgerald reiterated an &#34;overweight&#34; rating on shares of Bright Minds Biosciences in a report on Monday, December 1st. Wall Street Zen downgraded shares of Bright Minds Biosciences from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Friday, October 3rd. Finally, BTIG Research began coverage on Bright Minds Biosciences in a research report on Monday, September 8th. They issued a &#34;buy&#34; rating and a $72.00 price target for the company.</p>
<div class="lb-trans"><p>DRUG 最近成为几份研究报告的主题。Chardan Capital 在 11 月 19 日的研究报告中将 Bright Minds Biosciences 的股票评级上调至 “强烈买入”。Zacks Research 在 12 月 2 日的报告中将 Bright Minds Biosciences 的股票评级从 “强烈买入” 下调至 “持有”。Cantor Fitzgerald 在 12 月 1 日的报告中重申了对 Bright Minds Biosciences 股票的 “增持” 评级。Wall Street Zen 在 10 月 3 日的研究报告中将 Bright Minds Biosciences 的股票评级从 “持有” 下调至 “卖出”。最后，BTIG Research 在 9 月 8 日的研究报告中开始覆盖 Bright Minds Biosciences，给予 “买入” 评级和 72.00 美元的价格目标。</p>
</div><p><strong>Get Our Latest Stock Report on DRUG</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 DRUG 的最新股票报告</strong></p>
</div><h2>Hedge Funds Weigh In On Bright Minds Biosciences</h2>
<div class="lb-trans"><h2>对 Bright Minds Biosciences 的对冲基金看法</h2>
</div><ul>
<li>Bright Minds Biosciences Stock Surges Almost 1,500%</li>
</ul>
<div class="lb-trans"><ul>
<li>Bright Minds Biosciences 股票暴涨近 1500%</li>
</ul>
</div><p>Institutional investors have recently modified their holdings of the company. Braidwell LP acquired a new position in shares of Bright Minds Biosciences during the third quarter valued at about $18,422,000. Vivo Capital LLC increased its stake in Bright Minds Biosciences by 99.4% during the third quarter. Vivo Capital LLC now owns 501,617 shares of the company's stock valued at $30,428,000 after acquiring an additional 250,045 shares during the period. Balyasny Asset Management L.P. acquired a new position in Bright Minds Biosciences in the 3rd quarter valued at approximately $11,339,000. Millennium Management LLC lifted its position in shares of Bright Minds Biosciences by 376.9% in the 1st quarter. Millennium Management LLC now owns 192,557 shares of the company's stock worth $6,946,000 after acquiring an additional 152,178 shares during the period. Finally, Adage Capital Partners GP L.L.C. grew its holdings in shares of Bright Minds Biosciences by 50.9% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 200,000 shares of the company's stock worth $7,214,000 after purchasing an additional 67,500 shares in the last quarter. Institutional investors own 40.52% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者最近调整了对该公司的持股。Braidwell LP 在第三季度以约 18422000 美元的估值收购了 Bright Minds Biosciences 的新头寸。Vivo Capital LLC 在第三季度将其在 Bright Minds Biosciences 的股份增加了 99.4%。Vivo Capital LLC 现在拥有 501,617 股该公司的股票，估值为 30428000 美元，此前在此期间又收购了 250,045 股。Balyasny Asset Management L.P. 在第三季度以约 11339000 美元的估值收购了 Bright Minds Biosciences 的新头寸。Millennium Management LLC 在第一季度将其在 Bright Minds Biosciences 的股份增加了 376.9%。Millennium Management LLC 现在拥有 192,557 股该公司的股票，价值 6946000 美元，此前在此期间又收购了 152,178 股。最后，Adage Capital Partners GP L.L.C. 在第一季度将其在 Bright Minds Biosciences 的股份增加了 50.9%。Adage Capital Partners GP L.L.C. 现在拥有 200,000 股该公司的股票，价值 7214000 美元，此前在上个季度又购买了 67,500 股。机构投资者持有该公司 40.52% 的股票。</p>
</div><h2>Bright Minds Biosciences Price Performance</h2>
<div class="lb-trans"><h2>Bright Minds Biosciences 价格表现</h2>
</div><p>DRUG opened at $88.83 on Thursday. The company has a market capitalization of $691.95 million, a PE ratio of -95.51 and a beta of -6.22. Bright Minds Biosciences has a fifty-two week low of $23.17 and a fifty-two week high of $97.75. The business has a 50-day moving average of $65.84 and a 200-day moving average of $47.14.</p>
<div class="lb-trans"><p>DRUG 周四开盘价为 88.83 美元。该公司的市值为 6.9195 亿美元，市盈率为-95.51，贝塔值为-6.22。Bright Minds Biosciences 的 52 周低点为 23.17 美元，52 周高点为 97.75 美元。该公司的 50 日移动平均线为 65.84 美元，200 日移动平均线为 47.14 美元。</p>
</div><h2>About Bright Minds Biosciences</h2>
<div class="lb-trans"><h2>关于 Bright Minds Biosciences</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Bright Minds Biosciences Inc, a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder.</p>
<div class="lb-trans"><p>Bright Minds Biosciences Inc. 是一家生物技术公司，开发治疗药物以改善美国患者的生活，特别是那些患有严重和改变生活的疾病。其选择性 5-HT 受体激动剂的产品组合包括用于治疗癫痫、疼痛和神经精神疾病的 5-HT2C、5-HT2A 和 5-HT2C/A，以及完成针对未披露癫痫病的 1 期试验的 BMB-101。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Bright Minds Biosciences</li>
<li>The 3 Best Blue-Chip Stocks to Buy Now</li>
<li>Post 35% Surge, Analysts Eye More Upside in Copper Giant Freeport</li>
<li>The Significance of Brokerage Rankings in Stock Selection</li>
<li>Why a SpaceX IPO Could Be a Major Catalyst for GOOGL Stock</li>
<li>Stock Sentiment Analysis: How it Works</li>
<li>Can Upwork Maintain Its Comeback? Reasons to Be Bullish and Bearish</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Bright Minds Biosciences</li>
<li>现在购买的三只最佳蓝筹股</li>
<li>在上涨 35% 后，分析师关注铜业巨头 Freeport 的更多上涨空间</li>
<li>券商排名在股票选择中的重要性</li>
<li>为什么 SpaceX 的 IPO 可能成为 GOOGL 股票的重大催化剂</li>
<li>股票情绪分析：如何运作</li>
<li>Upwork 能否维持其复苏？看涨和看跌的理由</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFJVRw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=DRUG"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Bright Minds Biosciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Bright Minds Biosciences 吗？</h2>
</div><p>Before you consider Bright Minds Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Bright Minds Biosciences 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bright Minds Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Bright Minds Biosciences 并不在名单上。</p>
</div><p>While Bright Minds Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Bright Minds Biosciences 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Bright Minds Biosciences Inc.（纳斯达克股票代码：DRUG）被券商一致推荐为 “买入” 评级